Brief: BriaCell Therapeutics Expands Breast Cancer Platform Technology Into Prostate, Melanoma, And Lung Cancers
16/06/2021 13:38
June 16 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BRIACELL THERAPEUTICS EXPANDS BREAST CANCER PLATFORM
TECHNOLOGY
INTO PROSTATE, MELANOMA, AND LUNG CANCERS
* BRIACELL THERAPEUTICS - BRIA-OTS, AN OFF-THE-SHELF
PERSONALIZED
IMMUNOTHERAPY FOR ADVANCED BREAST CANCER, REMAINS ON TRACK TO
ENTER CLINIC IN 2021
* BRIACELL THERAPEUTICS CORP - ANTICIPATES COMMENCING
CLINICAL
TRIALS FOR THE NOVEL THERAPIES IN 2022
Source text for Eikon: ID:nGNX9T6wcg
Further company coverage: BCT.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study